Abstract:
The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: (I) alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
Abstract:
Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
Abstract:
Disclosed are polypeptides and nucleic acids encoding same. Also disclodes are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.
Abstract:
Disclosed are polypeptides and nucleic acids encoding same. Also disclodes are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.
Abstract:
Genetic polymorphisms in the 2C19*2 gene are useful as biomarkers for diagnosing an increased risk for high platelet reactivity or increased bleeding in a subject suffering from a cardiovascular disorder. In particular, the invention relates to methods of treating and preventing coronary artery disease using P2Y-12 receptor inhibitors. In addition, the present invention relates to kits for use in identifying patients with coronary heart disease with an increased risk for high platelet reactivity or increased bleeding.
Abstract:
Methods of modulating platelet procoagulant response are taught herein. Inhibition of platelet procoagulant response with agents that inhibit the Ca 2 +-sensitive K + channels, or Gardos channels, preferably while maintaining platelet bleeding arrest function, may be used to treat a variety of disorders.
Abstract:
The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4 (6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.
Abstract:
Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses tehrapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.